Robert Barrow is Chief Executive Officer of Definium Therapeutics, Inc. (DFTX). The company reported total compensation of $12,767,442 for fiscal year 2025.
| Salary | $655,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $11,719,750 |
| Option awards | $0 |
| Non-equity incentive plan | $378,263 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $14,429 |
| Total | $12,767,442 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Definium Therapeutics, Inc. filed April 27, 2026, accession 0001193125-26-182034.
| Peer-group chief executive median | $5,229,175 |
|---|---|
| Difference from that median | $7,538,267 |
| Percentile within the disclosed peer group | 93rd |
| Peers with a disclosed figure | 14 |
Medians and percentiles are computed across the peer group Definium Therapeutics, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Robert Barrow this page | Chief Executive Officer | $12,767,442 |
| Brandi Roberts | Chief Financial Officer | $5,116,362 |
| Daniel Karlin | Chief Medical Officer | $4,001,258 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Definium Therapeutics, Inc. compensation brief.
Robert Barrow's compensation sits inside Definium Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.